23andMe Holding Co. (ME) Return on Invested Capital (ROIC): -553.10%
Is 23andMe Holding Co.’s return on invested capital (ROIC) high or low?
23andMe Holding Co.'s return on invested capital (ROIC) of -553.10% is 283% below its 5-year average of -144.41%, near the low end of its 5-year range (-553.10%–-24.66%).
As of Monday, June 15, 2026. 65.27% below its 12-month average of -334.66%.
ME Return on Invested Capital (ROIC) Chart
ME Average Return on Invested Capital (ROIC) Chart
ME Current vs Average Return on Invested Capital (ROIC) Chart
ME Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
-553.10%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-334.66%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-183.52%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-144.41%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-65.27%
CURRENT VS 3Y AVG
-201.38%
CURRENT VS 5Y AVG
-283.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -553.10% | -334.66% | -183.52% | -144.41% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 5.67% | -6.15% | -6.50% | -3.41% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 6.02% | 9.35% | -2.77% | -9.72% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 2.04% | 2.21% | 2.35% | 2.39% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -10.29% | -59.01% | -58.33% | -53.58% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 8.36% | 4.65% | 6.09% | 6.66% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -24.28% | -15.13% | -6.38% | -2.73% |
| Baxter International Inc. (BAX)vs › | $10.77B | -1.79% | -0.86% | -2.61% | 0.30% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 9.94% | 9.96% | 10.13% | 11.66% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 3.98% | 4.09% | 3.90% | 4.29% |
Capital Efficiency
ROIC
-553.1%
ROE
-721.8%
23andMe Holding Co. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for 23andMe Holding Co. (ME)?
- The return on invested capital (ROIC) for ME stock is -553.10%.
- Is 23andMe Holding Co.'s return on invested capital (ROIC) high or low?
- 23andMe Holding Co.'s return on invested capital (ROIC) of -553.10% is 283% below its 5-year average of -144.41%, near the low end of its 5-year range (-553.10%–-24.66%).
- What is the TTM average return on invested capital (ROIC) for 23andMe Holding Co. (ME)?
- The TTM average return on invested capital (ROIC) for ME stock is -334.66%.
- What is the 3Y average return on invested capital (ROIC) for 23andMe Holding Co. (ME)?
- The 3Y average return on invested capital (ROIC) for ME stock is -183.52%.
- What is the 5Y average return on invested capital (ROIC) for 23andMe Holding Co. (ME)?
- The 5Y average return on invested capital (ROIC) for ME stock is -144.41%.
23andMe Holding Co. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-03-31 | -553.10% |
| 2024-03-31 | -116.22% |
| 2023-03-31 | -40.11% |
| 2022-03-31 | -24.66% |
| 2021-03-31 | -54.03% |
| 2020-03-31 | -78.36% |
| 2019-03-31 | -37.03% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage